



General Assembly

Substitute Bill No. 186

February Session, 2022



**AN ACT CONCERNING COLLABORATIVE DRUG THERAPY
MANAGEMENT AGREEMENTS AND POLICIES.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 20-631 of the 2022 supplement to the general
2 statutes is repealed and the following is substituted in lieu thereof
3 (*Effective from passage*):

4 (a) For the purposes of this section:

5 (1) "Care-giving institution" has the same meaning as provided in
6 section 20-571;

7 (2) "Commissioner" means the Commissioner of Consumer
8 Protection;

9 (3) "Collaborative drug therapy care plan" means a written document
10 memorializing the outcome of the process through which a patient and
11 one or more health care providers discuss, review and agree on an
12 approach to achieve the patient's desired health outcome;

13 (4) "Collaborative drug therapy management agreement" means an
14 agreement between one or more qualified pharmacists and one or more
15 prescribing practitioners to manage the drug therapy of individual
16 patients, or a patient population, based on a written protocol or a
17 collaborative drug therapy care plan;

18 (5) "Collaborative drug therapy management policy" means a written
19 policy adopted by a care-giving institution under which one or more
20 qualified pharmacists manage the drug therapy of individual patients,
21 or a patient population, based on a written protocol or a collaborative
22 drug therapy care plan;

23 (6) "Pharmacist" has the same meaning as provided in section 20-571;

24 (7) "Prescribing practitioner" has the same meaning as provided in
25 section 20-571;

26 (8) "Provider-patient relationship" means a relationship between a
27 prescribing practitioner and a patient in which (A) the patient has made
28 a medical complaint, (B) the patient has provided such patient's medical
29 history, (C) the patient has received a physical examination, and (D)
30 there exists a logical connection between such medical complaint,
31 medical history and physical examination and any drug prescribed for
32 such patient; and

33 (9) "Qualified pharmacist" means a pharmacist who (A) is deemed
34 competent under regulations adopted by the commissioner pursuant to
35 subsection (e) of this section, and (B) has reviewed the latest edition of
36 the "Pharmacists' Patient Care Process" published by the Joint
37 Commission of Pharmacy Practitioners.

38 [(a)] (b) Except as provided in section 20-631b, one or more qualified
39 pharmacists [licensed under this chapter who are determined
40 competent in accordance with regulations adopted pursuant to
41 subsection (d) of this section] may enter into a [written protocol-based]
42 collaborative drug therapy management agreement [with one or more
43 physicians licensed under chapter 370 or advanced practice registered
44 nurses licensed under chapter 378 to] or manage the drug therapy of
45 individual patients, or a patient population, under a collaborative drug
46 therapy management policy. In order to enter into a [written protocol-
47 based] collaborative drug therapy management agreement [, such
48 physician or advanced practice registered nurse shall have established]

49 or collaborative drug therapy care plan, or operate under a collaborative
50 drug therapy management policy, a prescribing practitioner must first
51 establish a provider-patient relationship with the patient or patients
52 who will receive collaborative drug therapy. Each patient's collaborative
53 drug therapy management shall be [governed by a written protocol
54 which may include guideline-directed management established by the
55 treating physician or advanced practice registered nurse in consultation
56 with the pharmacist. For purposes of this subsection, a "provider-patient
57 relationship" is a relationship based on (1) the patient making a medical
58 complaint, (2) the patient providing a medical history, (3) the patient
59 receiving a physical examination, and (4) a logical connection existing
60 between the medical complaint, the medical history, the physical
61 examination and any drug prescribed for the patient] based on a
62 diagnosis made by such patient's prescribing practitioner or a specific
63 test set forth in a collaborative drug therapy management agreement or
64 collaborative drug therapy management policy.

65 [(b)] (c) A collaborative drug therapy management agreement or
66 collaborative drug therapy management policy may authorize a
67 [pharmacist to implement] qualified pharmacist or qualified
68 pharmacists to initiate, modify, continue, discontinue or deprescribe a
69 drug therapy that has been prescribed for a patient, order associated
70 laboratory tests and administer drugs, all in accordance with a patient-
71 specific or patient population-specific written protocol [. Such
72 agreement] or collaborative drug therapy care plan, but may not
73 authorize a qualified pharmacist or qualified pharmacists to establish a
74 port to administer parenteral drugs. A collaborative drug therapy
75 management agreement or collaborative drug therapy management
76 policy may specifically address issues that may arise during a
77 medication reconciliation and concerns related to polypharmacy that
78 enable an authorized qualified pharmacist or qualified pharmacists to
79 [implement] initiate, modify, continue, discontinue or deprescribe drug
80 therapy. In instances where drug therapy is discontinued or
81 deprescribed, the qualified pharmacist or qualified pharmacists shall
82 notify the [treating physician or advanced practice registered nurse]

83 prescribing practitioner of such discontinuance or deprescribing [no]
84 not later than twenty-four hours [from the time of such discontinuance
85 or deprescribing] after such drug therapy is discontinued or
86 deprescribed. Each written protocol or collaborative drug therapy care
87 plan developed, pursuant to [the] a collaborative drug therapy
88 management agreement or collaborative drug therapy management
89 policy, shall contain detailed direction concerning the actions that the
90 qualified pharmacist or qualified pharmacists may perform for [that] the
91 patient [. The] or patient population. Such written protocol or
92 collaborative drug therapy care plan shall include, but need not be
93 limited to, (1) the specific drug or drugs, therapeutic class of drug or
94 classes of drugs, or medical devices to be managed by the qualified
95 pharmacist or qualified pharmacists, (2) the terms and conditions under
96 which drug therapy may be [implemented] initiated, modified,
97 continued, discontinued or deprescribed, (3) the conditions and events
98 upon which the qualified pharmacist is, or qualified pharmacists are,
99 required to notify the [physician or advanced practice registered nurse,
100 and] prescribing practitioner, (4) the laboratory tests that may be
101 ordered, and (5) a definition of the patient population included in such
102 written protocol or collaborative drug therapy care plan. All activities
103 performed by the qualified pharmacist or qualified pharmacists in
104 conjunction with the protocol shall be documented in the patient's
105 medical record [. The pharmacist shall report any encounters within the
106 scope of the collaborative drug therapy management agreement within
107 thirty days to the physician or advanced practice registered nurse
108 regarding the patient's drug therapy management or document such
109 information within a shared medical record. The] in accordance with all
110 applicable care-giving institution policies. Each collaborative drug
111 therapy management agreement, [and protocols] collaborative drug
112 therapy management policy, written protocol and collaborative drug
113 therapy care plan shall be available for inspection by the [Departments]
114 Department of Consumer Protection and the Department of Public
115 Health, [and Consumer Protection.] A copy of the protocol shall be filed
116 in the patient's medical record.

117 [(c)] (d) A pharmacist shall be responsible for demonstrating, in
118 accordance with regulations adopted pursuant to subsection [(d)] (e) of
119 this section, the competence necessary for [participation] the pharmacist
120 to participate in each collaborative drug therapy management
121 agreement, [into which such pharmacist enters] collaborative drug
122 therapy management policy and collaborative drug therapy care plan in
123 which such pharmacist seeks to participate by, among other things,
124 demonstrating that such pharmacist has reviewed the latest edition of
125 the "Pharmacists' Patient Care Process" published by the Joint
126 Commission of Pharmacy Practitioners.

127 [(d)] (e) The Commissioner of Consumer Protection, in consultation
128 with the Commissioner of Public Health, shall (1) adopt regulations, in
129 accordance with chapter 54, concerning competency requirements for
130 participation in a [written protocol-based] collaborative drug therapy
131 management agreement, [described in subsection (a) of this section,] the
132 minimum content of the collaborative drug therapy management
133 agreement [and the written protocol] and such other matters said
134 commissioners deem necessary to carry out the purpose of this section,
135 and (2) on or after the effective date of this section, amend such
136 regulations to include competency requirements for participation in a
137 collaborative drug therapy management policy or collaborative drug
138 therapy care plan and the minimum content of collaborative drug
139 therapy management policies, collaborative drug therapy care plans
140 and written protocols governing collaborative drug therapy
141 management.

142 Sec. 2. Section 19a-521d of the general statutes is repealed and the
143 following is substituted in lieu thereof (*Effective from passage*):

144 A medical director of a nursing home facility, as defined in section
145 19a-521, may establish protocols for a prescription drug formulary
146 system in accordance with guidelines established by the American
147 Society of Health-System Pharmacists and any applicable collaborative
148 drug therapy management agreement or collaborative drug therapy
149 management policy, as [described] defined in section 20-631, as

